VA issues Reclast drug monograph and criteria
This is a discussion on VA issues Reclast drug monograph and criteria within the Comparative Effectiveness Updates forum, part of the Industry News and Updates category; The United States Department of Veterans Affairs (VA) issued a drug monograph and "criteria for use" for zoledronic ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
01-29-2009, 01:39 PM
|
||||
|
||||
VA issues Reclast drug monograph and criteria
The United States Department of Veterans Affairs (VA) issued a drug monograph and "criteria for use" for zoledronic acid (Reclast). For patients with osteoporosis and no history of prior fractures, Reclast is positioned in cases of history or risk of upper GI bleed due to intolerance of oral bisphosphonates. Diagnosis criteria, calcium intake and vitamin D use are also included in the criteria.
Additional sources: VA PBM Services: Drug Monographs VA PBM Services: Clinical Guidance/Criteria for Use Last edited by chantell.reagan : 04-02-2009 at 01:51 PM. 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Criteria for Testosterone Replacement Therapy | bamiteko | Managed Care Issues for Oral Drugs | 6 | 11-03-2008 02:33 PM |
| Lidoderm Patch Criteria | andrew.maiorini | Managed Care Issues for Oral Drugs | 4 | 10-29-2008 04:45 PM |
| Tysabri policy criteria | chantell.reagan | Managed Care Issues for Injectable Drugs | 0 | 09-25-2008 12:53 PM |
| FDA Safety Changes: Reclast, Celestone Soluspan, Cymbalta | industry_news | Other Clinical Pharmacy News | 0 | 09-24-2008 01:20 PM |
| Forteo policy criteria | sdpharmd | Managed Care Issues for Injectable Drugs | 2 | 08-21-2008 12:19 PM |
© 2008 DrugManagementForum™ powered by |
 |